Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Stock Short Interest Climbs 96.3%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 18,161 shares, a growth of 96.3% from the September 30th total of 9,250 shares. Based on an average daily trading volume, of 7,124 shares, the days-to-cover ratio is currently 2.5 days. Currently, 0.0% of the company’s shares are short sold.

Ascentage Pharma Group International Trading Down 3.9%

Ascentage Pharma Group International stock traded down $0.57 during mid-day trading on Monday, reaching $13.89. 433 shares of the company were exchanged, compared to its average volume of 6,909. Ascentage Pharma Group International has a 12 month low of $13.99 and a 12 month high of $34.50. The company has a fifty day simple moving average of $15.85 and a 200-day simple moving average of $20.20. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. As a group, equities analysts anticipate that Ascentage Pharma Group International will post -2.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Citizens Jmp started coverage on Ascentage Pharma Group International in a research report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. lowered their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th. Citigroup began coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective for the company. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, William Blair began coverage on shares of Ascentage Pharma Group International in a research note on Friday, October 16th. They set an “outperform” rating for the company. Two analysts have rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $43.90.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.